Qiming Venture Partners and Over 10 Portfolio Companies Named to 2024 China Healthcare Industry Investment Glory List
The list not only recognizes outstanding investment institutions, investors, and companies, but also provides directional guidance for the evolution of industry investment logic, redefines the value standards for talent, and brings positive momentum to the industrial ecosystem.
Recently, the 2024 China Healthcare Industry Investment and Financing Glory List, jointly released by CHC Medical Consulting and CITIC Securities, was officially unveiled. This annual list covers investment institutions, individual investors, and enterprises. Qiming Venture Partners and its portfolio companies received multiple awards.
In the institutional and investor categories, Qiming Venture Partners was named to the Top 20 Best Healthcare Investment Firms and Top 20 Best Biopharma Investment Firms; William Hu, Managing Partner at Qiming Venture Partners, was named to the Top 50 Most Influential Investors; and Kan Chen, Partner at Qiming Venture Partners and Co-Head of Healthcare, was named to the Top 50 Excellent Healthcare Investors.
Qiming Venture Partners
Selected for
Top 20 Best Healthcare Investment Firms
Top 20 Best Biopharma Investment Firms
William Hu, Managing Partner at Qiming Venture Partners
Selected for
Top 50 Most Influential Investors
Kan Chen, Partner at Qiming Venture Partners and Co-Head of Healthcare
Selected for
Top 50 Excellent Healthcare Investors
In the enterprise category, Qiming portfolio companies Shukun Technology, Cornerstone Robotics, Northmed, Tupu Medical, Jialiang Medical, and Dingke Medical were named to the Top 50 Most Influential Healthcare Enterprises; Sanegene Therapeutics, GenEdit, Ticore Biotech, ACX Instruments, and Shize Biotech were named to the Top 50 Most Investment-Worthy Healthcare Enterprises; and Touche Future, Ontime Micro, and Ze'an Biopharmaceutical received the Top 20 Best Emerging Healthcare Enterprise Award.
Shukun Technology, Cornerstone Robotics, Northmed
Tupu Medical, Jialiang Medical, Dingke Medical
Selected for
Top 50 Most Influential Healthcare Enterprises
Sanegene Therapeutics, GenEdit, Ticore Biotech
ACX Instruments, Shize Biotech
Selected for
Top 50 Most Investment-Worthy Healthcare Enterprises
Touche Future, Ontime Micro, Ze'an Biopharmaceutical
Selected for
Top 20 Best Emerging Healthcare Enterprise Award
As the healthcare industry advances toward high-quality development, the core role of investment institutions has evolved into that of an "innovation accelerator." The release of this year's list serves not only as recognition of outstanding investment institutions, but also as a directional guide for the evolution of industry investment logic — one that emphasizes the diverse co-creation of technological value, industrial value, and social value. Going forward, as the healthcare industry increasingly intersects with artificial intelligence, green technology, and other fields, investment institutions with strategic resolve, professional insight, and ecosystem integration capabilities will continue to lead the wave of industrial transformation.
Against the backdrop of the healthcare industry entering the "Value Investing 2.0 Era," the role of outstanding investors has evolved into that of catalysts for technological breakthroughs and architects of industrial upgrading. The release of this year's list is both a recognition of individual professional competence and a redefinition of talent value standards for the industry — investors with cross-cycle judgment, end-to-end resource integration capabilities, and awareness of social value creation are becoming the core driving force leading high-quality development in healthcare. Going forward, as artificial intelligence, gene technology, and other fields become more deeply integrated, investors will continue to leverage innovative capital to help China's healthcare industry secure a strategic position in global competition.
This year's evaluation paid particular attention to enterprises' performance in core technology breakthroughs, global market expansion, and accessible healthcare practices, emphasizing both sustainable commercial value growth and substantive contributions to public health system building. Listed companies generally demonstrated high efficiency in technology commercialization, strong industrial chain integration capabilities, and rapid responsiveness to clinical needs — their development paths provide replicable innovation paradigms for the industry. The release of this list is not only recognition of outstanding enterprises, but also positive guidance for the industrial ecosystem. Going forward, China's healthcare industry is expected to achieve higher-quality upgrading through technology breakthroughs, model innovation, and international cooperation, contributing Chinese wisdom to global health endeavors.
Source | CHC Medical Media
Past Highlights
Qiming Honors | Qiming Venture Partners and Nearly 20 Portfolio Companies Named to 2023 China Healthcare Industry Investment and Financing Glory List Qiming Stars | 3 Qiming Portfolio Companies Named to KPMG China Biotech Innovation Pioneer 50 Qiming Honors | Qiming Venture Partners and Over 50 Portfolio Companies Named to 2025 Future Healthcare 100 List
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in early- and growth-stage outstanding enterprises in Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), Sinocelltech (688520.SH), Yuanxin Technology, ClinChoice, Belief BioMed, Biren Technology, and others.